Understanding how genetic mutations affect cancer treatment response in advanced solid tumours
Official title: Understanding the Molecular Pathways Underlying Drug Response and Resistance in Early Clinical Trials Through Tumour Molecular Characterisation
Run by Institute of Cancer Research, United Kingdom · NCT07737509 · Data updated 2026-11-12
This study tests whether mutations found in tumor and blood samples can help predict who will benefit from early-phase cancer treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Institute of Cancer Research, United Kingdom Academic / other |
| Locations | 2 sites (Sutton and 1 other locations) |
| Status | Recruiting |
| Started | April 28, 2021 |
| Main results expected | June 2036 |
| Study ends | June 2036 |
| Registry record updated | July 31, 2026 |
| Trial ID | NCT07737509 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with an advanced solid tumour who are being considered for or are participating in an early-phase clinical trial.
✕Probably not a fit
Patients whose tumours do not show actionable mutations or whose mutations do not predict response may not see a direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study enrolling adults with advanced solid cancers who are either being considered for or are already in early-phase clinical trials. Researchers will analyze existing tumor tissue and blood samples to identify genetic mutations and how these mutations change over time. The goal is to see if specific mutations correlate with responses or resistance to therapies, aiding better matching to trials and personalized treatment options.
Why it matters
Potential benefit: If successful, results could improve how patients are matched to trials and personalize treatment choices based on tumor genetics.
How similar studies have gone: Previous work in tumor molecular characterization has shown promise in guiding trial matching and understanding drug response, though this exact approach in early-phase trials is still evolving.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically, cytologically or biochemically confirmed diagnosis of advanced solid cancer 2. Older than or equal to 18 years of age 3. Patients who are being considered for an early phase clinical trial or who are currently participating in an early phase clinical trial 4. Written (signed and dated) informed consent. Exclusion Criteria: N/A.
Where it's running
-
Royal Marsden NHS Foundation Trust - Drug Development Unit
Sutton, United Kingdom Recruiting -
Royal Marsden NHS Foundation Trust - Prostate Cancer Targeted Therapy Group
Sutton, United Kingdom Recruiting
Study contacts
- Study coordinator: Jessica Maudsley
- Email: MC2@icr.ac.uk
- Phone: +44 20 3437 6017
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing SIM0610 for adults with advanced solid tumors
This will test whether SIM0610 is safe and can shrink tumors in adults with locally advanced or metastatic solid cancers such as non-small cell lung, colorectal, liver, and head and neck cancers.
-
Evaluating a new treatment for advanced solid tumors
This study is testing a new treatment called BA1301 to see if it is safe and effective for adults with advanced solid tumors that haven't improved with other treatments.
-
LM-168 alone or combined with toripalimab for advanced solid tumors
This trial tests whether LM-168, given alone or together with the immunotherapy toripalimab, can shrink tumors or control disease in adults with advanced solid tumors.
-
Evaluating RC220 with Doxorubicin for Advanced Solid Tumours
This study is testing a new treatment called RC220, both alone and with doxorubicin, to see if it is safe and works for adults with advanced solid tumors.
-
Testing UCB4594 for advanced cancer treatment
This study is testing a new drug called UCB4594 to see if it can help treat advanced cancer by targeting a specific protein on cancer cells.
-
Testing EBC-129 for advanced solid tumors
This study is testing a new treatment called EBC-129, alone and with another drug, to see how safe it is and if it can help people with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.